Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR )周四宣布，即日起任命Douglas Ingram为董事。该公司目前市值26亿美元，过去一年回报率为-35%。 根据InvestingPro分析，尽管近期市场面临挑战，但该公司仍保持强劲的流动性。根据2024年11月25日与Sarepta Therapeutics, ...

(NASDAQ:ARWR), currently valued at $2.6 billion and showing a -35% return over the past year, announced on Thursday the appointment of Douglas Ingram as a director, effective immediately.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), currently valued at $2.6 billion and showing a -35% return over the past year, announced on Thursday the appointment of Douglas Ingram as a director, ...

1, 2025 when the charter takes effect. Doug Ingram, Sims’ opponent in the runoff, took to social media and said he supports ...

The company’s president and CEO, Doug Ingram, is set to join Arrowhead’s board of directors. Alongside the above news, Sarepta also announced that its board of directors has authorized a share ...